posted on 2022-04-08, 06:31authored byStanley KimbungStanley Kimbung, Hannah Painter, Adam Penn-Nicholson, Asma Toefy, Mzwandile Erasmus, Willem A. Hanekom, Thomas ScribaThomas Scriba, Rachel P.J Lai, Suzaan Marais, Helen A. Fletcher, Graeme Meintjes, Robert J. Wilkinson, Mark F. Cotton, Savita Pahwa, Mark J. Cameron, Elisa NemesElisa Nemes
RISK6 and DIAG3 signatures scores for a subset of ART-naïve HIV+ infants and young children who were enrolled into the observational multi-centered prospective clinical study in the International Maternal, Pediatric, Adolescent AIDS Clinical Trial (IMPAACT) network. Signature scores were
computed from gene expression measurements performed by
microfluidic RT-qPCR on mRNA derived from whole blood collected in
PAXgene tubes. Also include are signature scores computed from publish microarray datasets: GSE83892 and GSE58411
Funding
IMPAACT Leadership Group
National Institute of Allergy and Infectious Diseases